LBF20207PG42: Difference between revisions
No edit summary |
No edit summary |
||
| (18 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
| Line 4: | Line 6: | ||
|LipidBank=XPR1779 | |LipidBank=XPR1779 | ||
|LipidMaps=- | |LipidMaps=- | ||
|SysName=9- | |SysName=9-Oxo- (11alpha,15R) -dihydroxy-prosta- (cis-5,trans-13) -dien-1-oic acid | ||
|Common Name=&&15 (R) -Prostaglandin E_2&& | |Common Name=&&15(R) - Prostaglandin E_2&&9-Oxo- (11alpha,15R) -dihydroxy-prosta- (5Z,13E) -dien-1-oic acid&& | ||
|Source= | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
|Biological Activity=15(R)-PGE2 is shown to inhibit fertility at a dose of 1.0 mg in hamsters.[[Reference:Miller_WL:Sutton_MJ:,Prostaglandins,1976,11,77|{{RelationTable/GetFirstAuthor|Reference:Miller_WL:Sutton_MJ:,Prostaglandins,1976,11,77}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | |||
Latest revision as of 17:35, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1779 |
| LipidMaps | - |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20207PG42 |
| 15(R) - Prostaglandin E2 | |
|---|---|
| |
| Structural Information | |
| 9-Oxo- (11α,15R) -dihydroxy-prosta- (cis-5,trans-13) -dien-1-oic acid | |
| |
| Formula | C20H32O5 |
| Exact Mass | 352.224974134 |
| Average Mass | 352.46508 |
| SMILES | C(CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@@H](CC1=O)O)CC |
| Physicochemical Information | |
| 15(R)-PGE2 is shown to inhibit fertility at a dose of 1.0 mg in hamsters. Miller_WL et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
